[Efficacy of entecavir switching therapy in chronic hepatitis B patients with clevudine-induced myopathy].

Ji Won Lee, Young Jun Lee, Jong Joon Lee, Jung Ho Kim, Young Kul Jung, Oh Sang Kwon, Duck Joo Choi, Yun Soo Kim, Ju Hyun Kim

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Clevudine is a potent antiviral agent against HBV. However, long-term clevudine therapy may cause myopathy. This study was carried out to identify the efficacy of entecavir switching therapy in chronic hepatitis B patients experiencing clevudine-induced myopathy. One hundred forty six patients with chronic hepatitis B treated with 30 mg of clevudine per day for 73 weeks (range, 36-132 weeks) were enrolled. Among them, clevudine-induced myopathy occurred in 21 patients (14.4%) which was diagnosed if the patients had symptoms related to myopathy with concurrent CK and AST elevation. All the patients who were diagnosed as clevudine-induced myopathy stopped the therapy, and 17 patients (81%) were switched to entecavir 0.5 mg. The patients with clevudine-induced myopathy were switched to entecavir 0.5 mg for median 68 weeks, and all of them showed disappearance of clinical myopathic symptoms and normalization of CK and AST level within median 2.2 months. Eight patients (47%) were HBeAg positive before entecavir treatment, and HBeAg seroconversion was achieved in 2 patients (25%). HBV DNA level was elevated in 3 patients (17.6%) at the time when the patients were diagnosed as myopathy, all of them achieved virological response with entecavir switching therapy. ALT level was elevated in 3 patients (17.6%) before entecavir treatment, all of them showed normalization of ALT level. During entecavir therapy, genotypic resistance to entecavir or virological breakthrough was not noted. In chronic hepatitis B patients experiencing clevudine-induced myopathy, switching to entecavir 0.5 mg per day showed a resolution of myopathy and adequate viral suppression.

Original languageEnglish
Pages (from-to)30-36
Number of pages7
JournalThe Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
Volume61
Issue number1
Publication statusPublished - 2013 Jan 25
Externally publishedYes

Fingerprint

Chronic Hepatitis B
Muscular Diseases
Therapeutics
Hepatitis B e Antigens
Clevudine
entecavir
Antiviral Agents

ASJC Scopus subject areas

  • Medicine(all)

Cite this

[Efficacy of entecavir switching therapy in chronic hepatitis B patients with clevudine-induced myopathy]. / Lee, Ji Won; Lee, Young Jun; Lee, Jong Joon; Kim, Jung Ho; Jung, Young Kul; Kwon, Oh Sang; Choi, Duck Joo; Kim, Yun Soo; Kim, Ju Hyun.

In: The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, Vol. 61, No. 1, 25.01.2013, p. 30-36.

Research output: Contribution to journalArticle

Lee, Ji Won ; Lee, Young Jun ; Lee, Jong Joon ; Kim, Jung Ho ; Jung, Young Kul ; Kwon, Oh Sang ; Choi, Duck Joo ; Kim, Yun Soo ; Kim, Ju Hyun. / [Efficacy of entecavir switching therapy in chronic hepatitis B patients with clevudine-induced myopathy]. In: The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi. 2013 ; Vol. 61, No. 1. pp. 30-36.
@article{25bdea20550f424a9e4d7f42f23f2de6,
title = "[Efficacy of entecavir switching therapy in chronic hepatitis B patients with clevudine-induced myopathy].",
abstract = "Clevudine is a potent antiviral agent against HBV. However, long-term clevudine therapy may cause myopathy. This study was carried out to identify the efficacy of entecavir switching therapy in chronic hepatitis B patients experiencing clevudine-induced myopathy. One hundred forty six patients with chronic hepatitis B treated with 30 mg of clevudine per day for 73 weeks (range, 36-132 weeks) were enrolled. Among them, clevudine-induced myopathy occurred in 21 patients (14.4{\%}) which was diagnosed if the patients had symptoms related to myopathy with concurrent CK and AST elevation. All the patients who were diagnosed as clevudine-induced myopathy stopped the therapy, and 17 patients (81{\%}) were switched to entecavir 0.5 mg. The patients with clevudine-induced myopathy were switched to entecavir 0.5 mg for median 68 weeks, and all of them showed disappearance of clinical myopathic symptoms and normalization of CK and AST level within median 2.2 months. Eight patients (47{\%}) were HBeAg positive before entecavir treatment, and HBeAg seroconversion was achieved in 2 patients (25{\%}). HBV DNA level was elevated in 3 patients (17.6{\%}) at the time when the patients were diagnosed as myopathy, all of them achieved virological response with entecavir switching therapy. ALT level was elevated in 3 patients (17.6{\%}) before entecavir treatment, all of them showed normalization of ALT level. During entecavir therapy, genotypic resistance to entecavir or virological breakthrough was not noted. In chronic hepatitis B patients experiencing clevudine-induced myopathy, switching to entecavir 0.5 mg per day showed a resolution of myopathy and adequate viral suppression.",
author = "Lee, {Ji Won} and Lee, {Young Jun} and Lee, {Jong Joon} and Kim, {Jung Ho} and Jung, {Young Kul} and Kwon, {Oh Sang} and Choi, {Duck Joo} and Kim, {Yun Soo} and Kim, {Ju Hyun}",
year = "2013",
month = "1",
day = "25",
language = "English",
volume = "61",
pages = "30--36",
journal = "The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi",
issn = "1598-9992",
publisher = "Korean Society of Gastroenterology",
number = "1",

}

TY - JOUR

T1 - [Efficacy of entecavir switching therapy in chronic hepatitis B patients with clevudine-induced myopathy].

AU - Lee, Ji Won

AU - Lee, Young Jun

AU - Lee, Jong Joon

AU - Kim, Jung Ho

AU - Jung, Young Kul

AU - Kwon, Oh Sang

AU - Choi, Duck Joo

AU - Kim, Yun Soo

AU - Kim, Ju Hyun

PY - 2013/1/25

Y1 - 2013/1/25

N2 - Clevudine is a potent antiviral agent against HBV. However, long-term clevudine therapy may cause myopathy. This study was carried out to identify the efficacy of entecavir switching therapy in chronic hepatitis B patients experiencing clevudine-induced myopathy. One hundred forty six patients with chronic hepatitis B treated with 30 mg of clevudine per day for 73 weeks (range, 36-132 weeks) were enrolled. Among them, clevudine-induced myopathy occurred in 21 patients (14.4%) which was diagnosed if the patients had symptoms related to myopathy with concurrent CK and AST elevation. All the patients who were diagnosed as clevudine-induced myopathy stopped the therapy, and 17 patients (81%) were switched to entecavir 0.5 mg. The patients with clevudine-induced myopathy were switched to entecavir 0.5 mg for median 68 weeks, and all of them showed disappearance of clinical myopathic symptoms and normalization of CK and AST level within median 2.2 months. Eight patients (47%) were HBeAg positive before entecavir treatment, and HBeAg seroconversion was achieved in 2 patients (25%). HBV DNA level was elevated in 3 patients (17.6%) at the time when the patients were diagnosed as myopathy, all of them achieved virological response with entecavir switching therapy. ALT level was elevated in 3 patients (17.6%) before entecavir treatment, all of them showed normalization of ALT level. During entecavir therapy, genotypic resistance to entecavir or virological breakthrough was not noted. In chronic hepatitis B patients experiencing clevudine-induced myopathy, switching to entecavir 0.5 mg per day showed a resolution of myopathy and adequate viral suppression.

AB - Clevudine is a potent antiviral agent against HBV. However, long-term clevudine therapy may cause myopathy. This study was carried out to identify the efficacy of entecavir switching therapy in chronic hepatitis B patients experiencing clevudine-induced myopathy. One hundred forty six patients with chronic hepatitis B treated with 30 mg of clevudine per day for 73 weeks (range, 36-132 weeks) were enrolled. Among them, clevudine-induced myopathy occurred in 21 patients (14.4%) which was diagnosed if the patients had symptoms related to myopathy with concurrent CK and AST elevation. All the patients who were diagnosed as clevudine-induced myopathy stopped the therapy, and 17 patients (81%) were switched to entecavir 0.5 mg. The patients with clevudine-induced myopathy were switched to entecavir 0.5 mg for median 68 weeks, and all of them showed disappearance of clinical myopathic symptoms and normalization of CK and AST level within median 2.2 months. Eight patients (47%) were HBeAg positive before entecavir treatment, and HBeAg seroconversion was achieved in 2 patients (25%). HBV DNA level was elevated in 3 patients (17.6%) at the time when the patients were diagnosed as myopathy, all of them achieved virological response with entecavir switching therapy. ALT level was elevated in 3 patients (17.6%) before entecavir treatment, all of them showed normalization of ALT level. During entecavir therapy, genotypic resistance to entecavir or virological breakthrough was not noted. In chronic hepatitis B patients experiencing clevudine-induced myopathy, switching to entecavir 0.5 mg per day showed a resolution of myopathy and adequate viral suppression.

UR - http://www.scopus.com/inward/record.url?scp=84891702806&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891702806&partnerID=8YFLogxK

M3 - Article

VL - 61

SP - 30

EP - 36

JO - The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi

JF - The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi

SN - 1598-9992

IS - 1

ER -